AI——中国医疗行业的新引擎
作者：微信文章点击上方蓝字关注 获得更多深度洞察
China Healthcare Policy Pulse
中国健康政策脉动
CN
AI——中国医疗行业的新引擎
2025年，随着全国各地医保、卫健部门、超百家医疗机构、医药企业宣布接入DeepSeek R1大模型，人工智能正以前所未有的深度和广度渗透中国生物医药产业和医疗服务行业，从药物发现到临床试验，全面加速创新的进程。
AI技术正在重塑中国生物医药的产业格局，展现出以下发展趋势：
全流程深度融合——当前中国生物医药产业正在将AI贯穿药物研发、医学影像、辅助诊疗等全生命周期，以期实现智能化、高效化、便捷化的产业升级。
药物研发为核心——AI正在成为新药发现的关键驱动力，能够显著缩短研发周期、降低成本，并大幅提高靶点发现和化合物筛选的成功率。
资本与巨头入局——制药和医疗服务领域针对AI的投资活跃，市场前景广阔。在今年DeepSeek R1大模型爆火之前，腾讯、百度、华为等科技巨头已经纷纷布局，通过算法和算力优势与医疗界展开“AI+医疗”合作。
生成式AI崛起——以大模型为代表的生成式AI，在药物分子设计、个性化治疗方案生成等方面展现出巨大潜力，推动产业进入新范式。
AI技术在多个重大疾病领域展现出巨大的应用潜力，主要的应用领域包括肿瘤学、自身免疫疾病、神经科学和传染性疾病。当前，AI在生物医药价值链的每个环节都正在发挥关键作用。包括：
靶点发现——分析海量生物数据，识别新的药物作用靶点。
药物设计——生成和优化具有理想特性的候选药物分子。
临床前研究——预测药物的吸收、分布、代谢、排泄和毒性。
临床试验——优化试验设计，招募合适的患者，预测试验结果。
诊断与治疗——辅助影像判读，提供个性化治疗方案。
中国AI医疗领域已形成多元化的竞争格局，包括AI原生企业、传统药企和科技巨头。一批在AI技术服务和自研管线方面具有领先优势AI生物科技公司和将专业大模型应用到医疗服务与管理的科技企业正在受到资本市场的追捧。与此同时，传统药企与CRO公司也正在积极布局AI，通过自主研发与战略合作迭代药物研发的全链条。中国的互联网与科技巨头也正在利用其AI算法和平台优势，通过与传统药企、医疗机构和新兴AI企业的合作，深度介入医药和医疗服务产业的创新。
随着众多企业在不同细分领域的积极探索和布局，AI正在中国的为生物医药和医疗服务行业注入新动能。AI正在成为中国医疗行业的新引擎。
联系我们
如需了解更多医疗健康相关政策监测、宏观概览、专题分析或趋势展望，欢迎邮件联系 beijing@sandpipercomms.com咨询我司相关服务。
EN
AI – Powering a New Era in China's Healthcare Industry
Artificial intelligence is rapidly transforming China's biopharmaceutical industry and healthcare service sector. A clear sign of this shift is the widespread adoption of the DeepSeek R1 large model, which has already been integrated by entities nationwide, including local healthcare security administrations, health commissions, pharmaceutical companies, and more than a hundred medical institutions. From drug discovery to clinical trials, AI is accelerating innovation throughout the development process.
AI technology is reshaping China's biopharmaceutical and healthcare service industries, with several key trends emerging:
Deep Integration Across the Full Value Chain: AI is being applied across the entire lifecycle of drug research and development, medical imaging, and auxiliary diagnosis and treatment, driving upgrades towards greater intelligence, efficiency, and convenience.
Drug R&D at the Core: AI is playing an increasingly vital role in drug discovery by shortening research and development cycles, lowering costs, and improving the success rates of target identification and compound screening.
Capital and Tech Giants Entering the Fray: Investment in AI for the pharmaceutical and healthcare service sectors is gaining rapid traction, opening up a wide array of market opportunities. Even before the recent rise of the DeepSeek R1 large model this year, tech giants like Tencent, Baidu, and Huawei had strategically positioned themselves, leveraging their algorithmic and computational strengths to collaborate with the medical community on "AI + Healthcare" initiatives.
Rise of Generative AI: Powered by large models, generative AI is showing tremendous potential in drug molecule design and the development of personalised treatment plans, ushering the industry into a new paradigm.
AI technology is demonstrating immense application potential across several major disease areas, notably oncology, autoimmune diseases, neuroscience, and infectious diseases. Currently, AI plays a crucial role in each phase of the clinical development pipeline, including:
Target Discovery: Analysing large-volume biological datasets to identify new drug targets.
Drug Design: Generating and optimising drug molecule candidates with desirable properties.
Preclinical Research: Predicting drug absorption, distribution, metabolism, excretion, and toxicity.
Clinical Trials: Optimising trial design, selecting suitable patients, and forecasting trial outcomes.
Diagnosis and Treatment: Assisting image interpretation and enabling personalised treatment planning.
China's AI healthcare sector is becoming increasingly diversified and competitive, attracting AI startups, major tech giants, and traditional pharmaceutical firms. Those offering advanced AI technologies, building proprietary pipelines, or applying specialised large models to medical services and management are in high demand among investors.
Pharmaceutical companies and contract research organisations (CROs) are accelerating AI adoption, strengthening their drug R&D chains through in-house capabilities and strategic collaborations. Conversely, internet and tech giants are driving innovation by contributing AI algorithms and digital infrastructure, and collaborating with pharmaceutical companies, medical institutions, and emerging AI enterprises.
With numerous companies actively exploring and deploying AI across various sub-sectors, the technology is injecting new momentum into China's biopharmaceutical and healthcare service industries, fast becoming a core driver of growth.
Contact us
For more healthcare policy monitoring, insights, thematic analyses or industry trend outlooks, please contact beijing@sandpipercomms.com by email to learn about the services we provide.
相关推荐 Related Articles
01
中国创新药10年巨变
Chinese Innovative Drugs Making Great Achievement in 10 years
02
集采政策为何“一月两变”？政策延续性和可预期性成行业关注焦点
Trading Certainty for Flexibility? What's at Stake in China's VBP Reform Proposal
03
长期照护职业走向专业化，银发经济发展迎来新机遇
Professionalising Long-Term Care in an Ageing Society
_
Sandpiper 基誉公关
Sandpiper is a strategic communications and public affairs consultancy that supports clients in understanding China’s dynamic policy environment through monitoring, reports, and timely alerts. For any business inquiries about stakeholder and issue mapping, expanding government outreach, and cultivating media relations, or any other services, please email beijing@sandpipercomms.com.
基誉公关是一家战略传播和公共事务咨询公司。我们通过政策监测、解读和预警，帮助客户实时追踪、理解中国的政策动态和市场环境。如需了解利益相关方和议题规划、扩展政府人脉、媒体关系，或者有任何其他业务咨询，请发送邮件至beijing@sandpipercomms.com。
This material has been prepared by Sandpiper, a strategic communications and public affairs consultancy, in the belief that it is fair and not misleading. The information upon which this material is based was obtained from sources believed to be reliable, but has not been independently verified; we do not guarantee its accuracy. This communication is being provided for informational purposes only.
页:
[1]